Radient Pharmaceuticals Expands Distribution Partnership With GenWay Biotech to Penetrate Highly Strategic International Markets With Its Onko-Sure Cancer Test
Radient Pharmaceuticals Corporation (RPC) has announced that it has signed a 3-year marketing, sales and distribution agreement with GenWay Biotech Inc. Under the terms of the agreement, GenWay Biotech Inc. has non-exclusive rights to distribute RPC’s Onko-Sure(TM) in vitro diagnostic cancer (IVD) test in the European Union, Middle East (excluding Israel), United Kingdom and Russia; and is responsible for product sales and marketing in these markets.
For the full story, Click Here
- PSA test losing value in predicting prostate cancer
- Agennix Expands Talactoferrin Phase 3 FORTIS-M Registration Trial Globally
- FDA clearance to Ikonisys’ oncoFISH HER2 test
- NPL launches Linac to make cancer treatment safer
